# Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

> clinical trial · VERIFIED · 2026-07-17

Status: ACTIVE_NOT_RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Essential Thrombocythemia

- Company: Merck Sharp & Dohme LLC
- Sector: Essential Thrombocythemia
- Primary source: https://clinicaltrials.gov/study/NCT06456346

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.